345 Park Avenue,
New York,
New York 10154
United States,
(212) 546-4000
www.bms.com
Bristol-Myers Squibb Company is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb Company was originally established in 1887 and is based in New York City.
| Year | ≤ '12 | '13 | '14 | '15 | '16 | '17 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (1.8/yr) | # | 8 | - | 3 | 3 | 2 | 1 | 17 |
| vol | $19.8B | $1.2B | $1.6B | $320M | $22.9B | |||
| Sell (0.4/yr) | # | 6 | - | 1 | - | 1 | - | 8 |
| vol | $9.4B | $2.7B | $350M | $12.5B | ||||
| 25 | ||||||||
| Financial | Deals |
|---|---|
|
Sign-up to View
|
3 |
|
Sign-up to View
|
2 |
|
Sign-up to View
|
1 |
| Legal | Deals |
|---|---|
|
Sign-up to View
|
3 |
|
Sign-up to View
|
3 |
|
Sign-up to View
|
1 |
| Buy | # | TOTAL |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| TOTAL | Sign-up to View | |
| Largest |
Dupont Pharmaceuticals Company $7.8B (2001-10-02) |
|
| Sell | # | Total |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| Total | Sign-up to View | |
| Largest |
Clairol, Inc. $5.0B (2001-05-22) |
|
According to our data here at Mergr, Bristol-Myers Squibb has acquired 20 companies, including 9 in the last 5 years. A total of 7 acquisitions came from private equity firms. It has also divested 8 assets.
Bristol-Myers Squibb’s largest acquisition to date was in 2001, when it acquired Dupont Pharmaceuticals Company for $7.8B. It’s largest disclosed sale occurred in 2001, when it sold Clairol to The Procter & Gamble for $5.0B. Bristol-Myers Squibb has acquired in 7 different US states, and 4 countries. The Company’s most targeted sectors include life science (100%).
When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 419 life science companies that have made at least 1 acquisition, 25 have acquired at least 5 companies, and 4 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 24 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.
Join Mergr and gain access to Bristol-Myers Squibb’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.
No obligation. Cancel anytime.
